Cargando…
Development and Evaluation of an FDM Printed Nasal Device for CPZ Solid Nanoparticles
Nasal drug delivery has been a focus of scientific interest for decades. A number of drug delivery systems and devices are available and have been highly successful in providing better and more comfortable therapy. The benefits of nasal drug delivery are not in question. The nasal surface provides a...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254643/ https://www.ncbi.nlm.nih.gov/pubmed/37298882 http://dx.doi.org/10.3390/molecules28114406 |
_version_ | 1785056691670220800 |
---|---|
author | To Quoc, Thinh Bíró, Krisztina Pető, Ágota Kósa, Dóra Sinka, Dávid Lekli, István Kiss-Szikszai, Attila Budai, István Béres, Mónika Vecsernyés, Miklós Fehér, Pálma Bácskay, Ildikó Ujhelyi, Zoltán |
author_facet | To Quoc, Thinh Bíró, Krisztina Pető, Ágota Kósa, Dóra Sinka, Dávid Lekli, István Kiss-Szikszai, Attila Budai, István Béres, Mónika Vecsernyés, Miklós Fehér, Pálma Bácskay, Ildikó Ujhelyi, Zoltán |
author_sort | To Quoc, Thinh |
collection | PubMed |
description | Nasal drug delivery has been a focus of scientific interest for decades. A number of drug delivery systems and devices are available and have been highly successful in providing better and more comfortable therapy. The benefits of nasal drug delivery are not in question. The nasal surface provides an excellent context for the targeted delivery of active substances. In addition to the large nasal surface area and intensive absorption, the active substances delivered through the nose overcome the blood–brain barrier and can be delivered directly to the central nervous system. Formulations for nasal administration are typically solutions or liquid dispersed systems such as emulsions or suspensions. Formulation techniques for nanostructures have recently undergone intensive development. Solid-phase heterogeneous dispersed systems represent a new direction in pharmaceutical formulations. The wide range of possible examples and the variety of excipients allow for the delivery of a wide range of active ingredients. The aim of our experimental work was to develop a solid drug delivery system that possesses all of the above-mentioned advantageous properties. In developing solid nanosystems, we not only exploited the advantages of size but also the adhesive and penetration-enhancing properties of excipients. During formulation, several amphiphilic compounds with adhesion properties and penetration enhancing effects were incorporated. We used chlorpromazine (CPZ), which is mainly used in the treatment of psychotic disorders such as schizophrenia and bipolar disorder. Chlorpromazine has been previously investigated by our team in other projects. With the availability of previous methods, the analytical characterization of the drug was carried out effectively. Due to the frequent and severe side effects of the drug, the need for therapeutic dose reduction is indisputable. In this series of experiments, we succeeded in constructing drug delivery systems. Finely divided Na nanoparticles were formed using a Büchi B90 nanospray dryer. An important step in the development of the drug carrier was the selection of suitable inert carrier compounds. Particle size determination and particle size distribution analysis were performed to characterize the prepared nanostructures. As safety is the most important aspect of any drug formulation, all components and systems were tested with different biocompatibility assays. The tests performed demonstrated the safe applicability of our systems. The bioavailability of chlorpromazine was studied as a function of the ratio of the active ingredient administered nasally and intravenously. As described above, most nasal formulations are liquids, but our system is solid, so there is currently no tool available to accurately target this system. As a supplement of the project, a nasal dosing device was developed, corresponding to the anatomical structure; a prototype of the device was made using 3D FDM technology. Our results lay the foundation for the design and industrial scaling of a new approach to the design and production of a high-bioavailability nasal medicinal product. |
format | Online Article Text |
id | pubmed-10254643 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102546432023-06-10 Development and Evaluation of an FDM Printed Nasal Device for CPZ Solid Nanoparticles To Quoc, Thinh Bíró, Krisztina Pető, Ágota Kósa, Dóra Sinka, Dávid Lekli, István Kiss-Szikszai, Attila Budai, István Béres, Mónika Vecsernyés, Miklós Fehér, Pálma Bácskay, Ildikó Ujhelyi, Zoltán Molecules Article Nasal drug delivery has been a focus of scientific interest for decades. A number of drug delivery systems and devices are available and have been highly successful in providing better and more comfortable therapy. The benefits of nasal drug delivery are not in question. The nasal surface provides an excellent context for the targeted delivery of active substances. In addition to the large nasal surface area and intensive absorption, the active substances delivered through the nose overcome the blood–brain barrier and can be delivered directly to the central nervous system. Formulations for nasal administration are typically solutions or liquid dispersed systems such as emulsions or suspensions. Formulation techniques for nanostructures have recently undergone intensive development. Solid-phase heterogeneous dispersed systems represent a new direction in pharmaceutical formulations. The wide range of possible examples and the variety of excipients allow for the delivery of a wide range of active ingredients. The aim of our experimental work was to develop a solid drug delivery system that possesses all of the above-mentioned advantageous properties. In developing solid nanosystems, we not only exploited the advantages of size but also the adhesive and penetration-enhancing properties of excipients. During formulation, several amphiphilic compounds with adhesion properties and penetration enhancing effects were incorporated. We used chlorpromazine (CPZ), which is mainly used in the treatment of psychotic disorders such as schizophrenia and bipolar disorder. Chlorpromazine has been previously investigated by our team in other projects. With the availability of previous methods, the analytical characterization of the drug was carried out effectively. Due to the frequent and severe side effects of the drug, the need for therapeutic dose reduction is indisputable. In this series of experiments, we succeeded in constructing drug delivery systems. Finely divided Na nanoparticles were formed using a Büchi B90 nanospray dryer. An important step in the development of the drug carrier was the selection of suitable inert carrier compounds. Particle size determination and particle size distribution analysis were performed to characterize the prepared nanostructures. As safety is the most important aspect of any drug formulation, all components and systems were tested with different biocompatibility assays. The tests performed demonstrated the safe applicability of our systems. The bioavailability of chlorpromazine was studied as a function of the ratio of the active ingredient administered nasally and intravenously. As described above, most nasal formulations are liquids, but our system is solid, so there is currently no tool available to accurately target this system. As a supplement of the project, a nasal dosing device was developed, corresponding to the anatomical structure; a prototype of the device was made using 3D FDM technology. Our results lay the foundation for the design and industrial scaling of a new approach to the design and production of a high-bioavailability nasal medicinal product. MDPI 2023-05-29 /pmc/articles/PMC10254643/ /pubmed/37298882 http://dx.doi.org/10.3390/molecules28114406 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article To Quoc, Thinh Bíró, Krisztina Pető, Ágota Kósa, Dóra Sinka, Dávid Lekli, István Kiss-Szikszai, Attila Budai, István Béres, Mónika Vecsernyés, Miklós Fehér, Pálma Bácskay, Ildikó Ujhelyi, Zoltán Development and Evaluation of an FDM Printed Nasal Device for CPZ Solid Nanoparticles |
title | Development and Evaluation of an FDM Printed Nasal Device for CPZ Solid Nanoparticles |
title_full | Development and Evaluation of an FDM Printed Nasal Device for CPZ Solid Nanoparticles |
title_fullStr | Development and Evaluation of an FDM Printed Nasal Device for CPZ Solid Nanoparticles |
title_full_unstemmed | Development and Evaluation of an FDM Printed Nasal Device for CPZ Solid Nanoparticles |
title_short | Development and Evaluation of an FDM Printed Nasal Device for CPZ Solid Nanoparticles |
title_sort | development and evaluation of an fdm printed nasal device for cpz solid nanoparticles |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254643/ https://www.ncbi.nlm.nih.gov/pubmed/37298882 http://dx.doi.org/10.3390/molecules28114406 |
work_keys_str_mv | AT toquocthinh developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles AT birokrisztina developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles AT petoagota developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles AT kosadora developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles AT sinkadavid developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles AT lekliistvan developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles AT kissszikszaiattila developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles AT budaiistvan developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles AT beresmonika developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles AT vecsernyesmiklos developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles AT feherpalma developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles AT bacskayildiko developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles AT ujhelyizoltan developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles |